Tirzepatide works by stimulating both GIP and GLP-1 receptors. These incretin hormones regulate the release of insulin after meals, curb appetite, and slow down gastric emptying. While semaglutide targets only the GLP-1 receptor, tirzepatide’s dual action offers a more effective response, particularly in individuals with advanced metabolic disorders. https://biotechlabzsupply.com/